Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (738) 738
Publication (161) 161
Paper (104) 104
Patent (36) 36
Newspaper Article (7) 7
Book / eBook (6) 6
Conference Proceeding (3) 3
Book Chapter (1) 1
Book Review (1) 1
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (325) 325
male (243) 243
index medicus (242) 242
infectious diseases (227) 227
adult (226) 226
female (211) 211
middle aged (174) 174
hiv infections - drug therapy (169) 169
immunology (137) 137
hiv (125) 125
nuclear experiment (113) 113
experiment (111) 111
human immunodeficiency virus--hiv (96) 96
virology (95) 95
physics (91) 91
microbiology (88) 88
treatment outcome (87) 87
drug therapy (85) 85
nuclear physics (80) 80
anti-hiv agents - therapeutic use (77) 77
hiv infections - virology (75) 75
viral load (75) 75
life sciences (74) 74
aids (71) 71
hiv infection (71) 71
aids/hiv (70) 70
high energy physics - experiment (70) 70
antiretroviral therapy (69) 69
aged (65) 65
pharmacology & pharmacy (62) 62
antiretroviral drugs (61) 61
drug therapy, combination (58) 58
health aspects (57) 57
cd4 lymphocyte count (53) 53
emtricitabine (52) 52
therapy (52) 52
tenofovir (51) 51
anti-hiv agents - administration & dosage (50) 50
antiviral agents (50) 50
hiv-1 - drug effects (50) 50
infections (49) 49
particle physics (47) 47
high energy physics (46) 46
infection (46) 46
safety (46) 46
hiv-1 (45) 45
antiretroviral therapy, highly active (43) 43
hiv infections - complications (43) 43
research (43) 43
dosage and administration (42) 42
rna, viral - blood (42) 42
anti-hiv agents - adverse effects (40) 40
human health and pathology (38) 38
efficacy (37) 37
hiv infections - immunology (37) 37
human necessities (36) 36
hygiene (36) 36
medical or veterinary science (36) 36
preparations for medical, dental, or toilet purposes (36) 36
risk factors (36) 36
ritonavir (36) 36
patients (35) 35
[ phys.nexp ] physics [physics]/nuclear experiment [nucl-ex] (34) 34
analysis (34) 34
hiv-1 - genetics (34) 34
mutation (34) 34
adults (33) 33
specific therapeutic activity of chemical compounds ormedicinal preparations (33) 33
adolescent (32) 32
clinical trials (32) 32
chemistry (31) 31
efavirenz (31) 31
france (31) 31
general tagging of cross-sectional technologies spanning over several sections of the ipc (31) 31
general tagging of new technological developments (31) 31
heterocyclic compounds (31) 31
human-immunodeficiency-virus (31) 31
metallurgy (31) 31
organic chemistry (31) 31
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (31) 31
technologies for adaptation to climate change (31) 31
technologies or applications for mitigation or adaptation againstclimate change (31) 31
care and treatment (30) 30
medicine, general & internal (30) 30
risk (30) 30
medicine (29) 29
protease inhibitors (29) 29
viruses (29) 29
drug resistance, viral (28) 28
hepatitis (28) 28
[phys.nexp]physics [physics]/nuclear experiment [nucl-ex] (27) 27
disease (27) 27
drug administration schedule (27) 27
matematikk og naturvitenskap: 400::fysikk: 430::kjerne- og elementærpartikkelfysikk: 431 [vdp] (27) 27
mathematics and natural scienses: 400::physics: 430::nuclear and elementary particle physics: 431 [vdp] (27) 27
prevention (27) 27
reverse transcriptase inhibitors - therapeutic use (27) 27
rna (27) 27
young adult (27) 27
[phys.hexp]physics [physics]/high energy physics - experiment [hep-ex] (26) 26
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (747) 747
French (34) 34
Spanish (12) 12
German (5) 5
Hungarian (2) 2
Icelandic (2) 2
Norwegian (2) 2
Danish (1) 1
Polish (1) 1
Portuguese (1) 1
Russian (1) 1
Slovak (1) 1
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Prioritisation of subgroups for immediate antiretroviral therapy – Authors' reply
by Molina, Jean-Michel and Grund, Birgit
The Lancet HIV, ISSN 2352-3018, 05/2018, Volume 5, Issue 5, pp. e206 - e206
HIV Infections | Anti-HIV Agents | Humans | Pain Management
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
by Lundgren, Jens D and Babiker, Abdel G and Gordin, Fred and Emery, Sean and Grund, Birgit and Sharma, Shweta and Avihingsanon, Anchalee and Cooper, David A and Fätkenheuer, Gerd and Llibre, Josep M and Molina, Jean-Michel and Munderi, Paula and Schechter, Mauro and Wood, Robin and Klingman, Karin L and Collins, Simon and Clifford Lane, H and Phillips, Andrew N and Neaton, James D and The INSIGHT START Study Group and INSIGHT START Study Group
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 9, pp. 795 - 807
When to start antiretroviral therapy for HIV infection on the basis of the CD4+ count has been controversial. In a global randomized trial, treatment of... 
TREATMENT START TRIAL | MEDICINE, GENERAL & INTERNAL | BASE-LINE | CLINICAL-TRIALS | RISK | DEATH | OUTCOMES | SMART | INTERRUPTION | PARTICIPANTS | CELL COUNTS | Follow-Up Studies | Time-to-Treatment | Humans | Anti-Retroviral Agents - adverse effects | Kaplan-Meier Estimate | RNA, Viral - analysis | HIV Seropositivity - drug therapy | Male | CD4 Lymphocyte Count | HIV - isolation & purification | Asymptomatic Diseases | Viral Load | Anti-Retroviral Agents - administration & dosage | Adult | Female | HIV - genetics | HIV Seropositivity - immunology | Antiviral agents | Care and treatment | Usage | Clinical trials | Dosage and administration | Research | HIV (Viruses) | HIV infection | Studies | Antiretroviral drugs | Infectious diseases | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Hypersensitivity | Data processing | Drug therapy | Antiretroviral therapy | CD4 antigen
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Efficacy and safety of once-daily regimens in the treatment of HIV infection
by Molina, Jean-Michel
Drugs, ISSN 0012-6667, 2008, Volume 68, Issue 5, pp. 567 - 578
Early versions of highly-active antiretroviral therapy (HAART) characteristically involved complicated combinations of different drugs, which were taken as... 
Antiretrovirals, therapeutic use | Lopinavir/ritonavir, therapeutic use | HIV infections, treatment | LAMIVUDINE | COMBINATION THERAPY | EFAVIRENZ | EMTRICITABINE | EARLY VIROLOGICAL FAILURE | TENOFOVIR DF | RANDOMIZED-TRIAL | PHARMACOLOGY & PHARMACY | RETROVIRAL-NAIVE PATIENTS | TWICE-DAILY REGIMEN | ANTIRETROVIRAL THERAPY | TOXICOLOGY | Anti-HIV Agents - administration & dosage | Drug Administration Schedule | Anti-HIV Agents - adverse effects | Humans | HIV Infections - drug therapy | Patient Compliance | Randomized Controlled Trials as Topic
Journal Article
Details down arrow
4. Full Text On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
by Molina, Jean-Michel and Capitant, Catherine and Spire, Bruno and Pialoux, Gilles and Cotte, Laurent and Charreau, Isabelle and Tremblay, Cecile and Le Gall, Jean-Marie and Cua, Eric and Pasquet, Armelle and Raffi, François and Pintado, Claire and Chidiac, Christian and Chas, Julie and Charbonneau, Pierre and Delaugerre, Constance and Suzan-Monti, Marie and Loze, Benedicte and Fonsart, Julien and Peytavin, Gilles and Cheret, Antoine and Timsit, Julie and Girard, Gabriel and Lorente, Nicolas and Préau, Marie and Rooney, James F and Wainberg, Mark A and Thompson, David and Rozenbaum, Willy and Doré, Veronique and Marchand, Lucie and Simon, Marie-Christine and Etien, Nicolas and Aboulker, Jean-Pierre and Meyer, Laurence and Delfraissy, Jean-François and ANRS IPERGAY Study Grp and ANRS IPERGAY Study Group
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 23, pp. 2237 - 2246
In this trial of preexposure prophylaxis with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) in men who have sex with men, TDF-FTC was found to be... 
TRIAL | MEDICINE, GENERAL & INTERNAL | AFRICAN WOMEN | TRANSMISSION | ANTIRETROVIRAL PROPHYLAXIS | REDUCTION | EFFICACY | VACCINE | PREVENTION | HUMAN-IMMUNODEFICIENCY-VIRUS | TENOFOVIR | HIV-1 | HIV Infections - prevention & control | Emtricitabine - adverse effects | Emtricitabine - therapeutic use | Sexual Behavior | Tenofovir - adverse effects | Double-Blind Method | Tenofovir - therapeutic use | Humans | Middle Aged | Risk Factors | Kaplan-Meier Estimate | Male | Sexually Transmitted Diseases - epidemiology | Pre-Exposure Prophylaxis | Medication Adherence | Homosexuality, Male | Adult | Condoms - utilization | Drug Therapy, Combination | Emtricitabine | Antiretroviral drugs | Prophylaxis | Antiretroviral therapy | Tenofovir | Hepatitis | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Men | Condoms | Anal sex | Risk exposure | Drug therapy | Urine | Antigens | Infections | Prevention | Drug dosages | Public health | Index Medicus | Abridged Index Medicus | Psychology | Humanities and Social Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
by Sax, Paul E, Dr Prof and Wohl, David, MD and Yin, Michael T, Prof and Post, Frank, MD and DeJesus, Edwin, MD and Saag, Michael, MD and Pozniak, Anton, MD and Thompson, Melanie, MD and Podzamczer, Daniel, MD and Molina, Jean Michel, Prof and Oka, Shinichi, MD and Koenig, Ellen, MD and Trottier, Benoit, MD and Andrade-Villanueva, Jaime, MD and Crofoot, Gordon, MD and Custodio, Joseph M, PharmD and Plummer, Andrew, MS and Zhong, Lijie, PhD and Cao, Huyen, MD and Martin, Hal, MD and Callebaut, Christian, PhD and Cheng, Andrew K, MD and Fordyce, Marshall W, MD and McCallister, Scott, MD and GS-US-292-0104 0111 Study Team and GS-US-292-0104/0111 Study Team
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9987, pp. 2606 - 2615
Summary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide... 
Internal Medicine | KIDNEY-DISEASE | RATES | MEDICINE, GENERAL & INTERNAL | ABACAVIR-LAMIVUDINE | BONE-MINERAL DENSITY | SAFETY | ADULTS | ANTIRETROVIRAL THERAPY | LOPINAVIR/RITONAVIR | COUNT | EXPOSURE | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Arthralgia - chemically induced | Thiazoles - adverse effects | Sleep Initiation and Maintenance Disorders - chemically induced | Tenofovir | Adenine - adverse effects | Quinolones - adverse effects | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Headache - chemically induced | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Respiration Disorders - chemically induced | Double-Blind Method | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Nausea | Adenine - administration & dosage | Organophosphonates - administration & dosage | Bone Density - drug effects | Quinolones - administration & dosage | Carbamates - adverse effects | HIV Infections - drug therapy | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Medical colleges | Clinical trials | Cross infection | Nosocomial infections | HIV (Viruses) | Drug therapy | Health aspects | HIV infection | Analysis | Antiretroviral drugs | Infections | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Once-daily Doravirine in Human Immunodeficiency Virus Type 1–Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis
by Orkin, Chloe and Molina, Jean-Michel and Lombaard, Johan and DeJesus, Edwin and Rodgers, Anthony and Kumar, Sushma and Martin, Elizabeth and Hanna, George and Hwang, Carey
Clinical Infectious Diseases, ISSN 1058-4838, 05/2019
Abstract Background Doravirine (DOR) demonstrated noninferior efficacy to darunavir plus ritonavir (DRV+r) and efavirenz (EFV) in 2 ongoing phase 3 trials:... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
by DeJesus, Edwin and Rockstroh, Jürgen K, MD and Henry, Keith, MD and Molina, Jean-Michel, MD and Gathe, Joseph, MD and Ramanathan, Srinivasan, PhD and Wei, Xuelian, PhD and Yale, Kitty, MSc and Szwarcberg, Javier, MD and White, Kirsten, Prof and Cheng, Andrew K, MD and Kearney, Brian P, Prof and GS-236-0103 Study Team
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2429 - 2438
Summary Background The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI),... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | TREATMENT-NAIVE | PHARMACOKINETICS | RALTEGRAVIR | SAFETY | EFAVIRENZ | ADULTS | SINGLE-TABLET REGIMEN | PATIENTS 96-WEEK EFFICACY | COMBINATION | ADHERENCE | HIV-1 | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Atazanavir Sulfate | Adult | Female | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Ritonavir - administration & dosage | Deoxycytidine - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Quinolones - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | Patient outcomes | Dosage and administration | Research | Comparative analysis | Drug therapy | HIV infection | Anti-HIV agents | Antiretroviral drugs | Bone density | Pharmaceutical industry | Human immunodeficiency virus--HIV | Pneumonia | Laboratories | Ritonavir | Liver | Infections | Drug resistance | Hepatitis | Randomization | All terrain vehicles | Creatinine | Integrase | Data processing | Proteinase inhibitors | Behavior disorders | Ribonucleic acid--RNA | Patients | Cholesterol | Glomerular filtration rate | Inhibitors | Protease inhibitors | Interactive systems
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
by Molina, Jean-Michel, Dr, Prof and Cahn, Pedro, MD and Grinsztejn, Beatriz, MD and Lazzarin, Adriano, Prof and Mills, Anthony, MD and Saag, Michael, Prof and Supparatpinyo, Khuanchai, Prof and Walmsley, Sharon, Prof and Crauwels, Herta, PhD and Rimsky, Laurence T, PhD and Vanveggel, Simon, MSc and Boven, Katia, MD and ECHO Study Grp and ECHO study group
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 238 - 246
Summary Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected... 
Internal Medicine | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | COMBINATION THERAPY | GUIDELINES | PROTEASE-INHIBITOR | ANTIRETROVIRAL THERAPY | NEVIRAPINE | REGIMENS | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Dosage and administration | Efavirenz | Patient outcomes | Clinical trials | Antiretroviral drugs | Drug therapy | Human immunodeficiency virus--HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Tenofovir disoproxil fumarate-induced Fanconiʼs syndrome during HIV postexposure prophylaxis
by Penot, Pauline and Gosset, Clément and Verine, Jérôme and Molina, Jean-Michel
AIDS, ISSN 0269-9370, 05/2016, Volume 30, Issue 8, pp. 1311 - 1313
HIV Infections - prevention & control | Kidney Tubules, Proximal - pathology | Sexual Behavior | Tenofovir - adverse effects | Anti-HIV Agents - adverse effects | Humans | Middle Aged | Male | Treatment Outcome | Tenofovir - administration & dosage | Anti-HIV Agents - administration & dosage | Unsafe Sex | Post-Exposure Prophylaxis | Fanconi Syndrome - pathology | Fanconi Syndrome - chemically induced | Fanconi Syndrome - drug therapy | Kidney Tubules, Proximal - drug effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Doravirine: a review
by Colombier, Marie-Alice and Molina, Jean-Michel
Current Opinion in HIV and AIDS, ISSN 1746-630X, 05/2018, Volume 13, Issue 4, pp. 308 - 314
PURPOSE OF REVIEWThe current review addresses the role of doravirine (DOR), a novel once-daily nonnucleoside reverse transcriptase inhibitor (NNRTI) in... 
nonnucleoside reverse transcriptase inhibitor | antiretroviral naïve | drug resistance | doravirine | INFECTIOUS DISEASES | SINGLE | HEALTHY-SUBJECTS | IMMUNOLOGY | REVERSE-TRANSCRIPTASE INHIBITOR |